Optimizing Manufacturing: BD's Closure Strategy in Drogheda

BD Announces Closure of Manufacturing Plant in Drogheda

Medical devices manufacturer BD ( Becton , Dickinson and Company ) , listed on the NYSE as BDX , is set to close its facility in Drogheda , Co Louth , Ireland , resulting in the loss of around 200 jobs . This decision comes after a comprehensive review of the company 's manufacturing and supply chain operations , following a workforce reduction of 60 employees at the site a year ago . The closure is expected to be completed by September 2026 , with approximately 110 job cuts scheduled to begin next March.

The Drogheda site of BD , which has been operational for over six decades , is involved in the manufacturing of products for oncology , interventional radiology , and critical care . The company 's announcement to wind down operations at the site over the next two - and - a - half years is part of its broader 2025 strategy to optimize its manufacturing network and adjust production levels in line with current market conditions . BD aims to reallocate its resources efficiently to adapt to the changing landscape of the industry.

BD expressed its intention to collaborate with IDA Ireland , the government 's foreign direct investment arm , to identify a new owner for the Drogheda facility . Despite the closure of the Drogheda plant , the company reaffirmed its commitment to its other sites in Ireland , including locations in Dublin , Wexford , and Limerick . BD recently made significant investments in these sites , ensuring continued operations and growth in the region.

SIPTU manufacturing divisional organiser Neil McGowan emphasized the importance of government intervention to support the retention of manufacturing capabilities in the area , safeguarding the skills of the workforce at BD . The trade union is advocating for swift action to prevent the loss of infrastructure and expertise in Drogheda . BD 's workforce in Ireland totals 1,000 employees across all its sites , showcasing the company 's significant presence and contributions to the local economy.

In a statement issued to MassDevice , a BD spokesperson highlighted the company 's commitment to right - sizing its operations and aligning its manufacturing activities with industry dynamics . The phased closure of the Drogheda plant reflects BD 's strategic priorities and the need to streamline its global operations . As BD navigates the evolving landscape of the medical technology sector , the company remains focused on driving efficiency and innovation to sustain its market position.